Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,095 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MCG Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

NCT02214225
View directory record Official record
Conditions
Influenza, Human
Interventions
Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
3,484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
33
States / cities
Huntsville, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

NCT01010217
View directory record Official record
Conditions
Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
Interventions
Cyclophosphamide, Fludarabine, Melphalan, Mesna, Rituximab, Stem Cell Transplantation, Thiotepa, Tacrolimus, Mycofenolate mofetil, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 25, 2026, 11:25 AM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

NCT00315458
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
48
States / cities
Birmingham, Alabama • Haleyville, Alabama • Muscle Shoals, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 1Phase 2 Interventional

IVIG - West Nile Encephalitis: Safety and Efficacy

NCT00068055
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-lgG-am, Polygam® S/D, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Use of NPSP558 in the Treatment of Hypoparathyroidism

NCT00732615
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Placebo, NPSP558
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
19
States / cities
Scottsdale, Arizona • Lakewood, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Improving Outcomes in Neonatal Abstinence Syndrome

NCT01958476
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal
Interventions
Neonatal Morphine Solution, Methadone, Phenobarbital
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
8
States / cities
Jacksonville, Florida • Portland, Maine • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00660517
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
MP29-02, azelastine Hcl, fluticasone propionate, placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Not applicable Interventional Results available

A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain

NCT01269918
View directory record Official record
Conditions
Adult Intracranial Tumor, Adult Solid Tumor
Interventions
Remifentanil, Dexmedetomidine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Results available

Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus

NCT01721460
View directory record Official record
Conditions
Parkinson's Disease, Deep Brain Stimulation Surgery
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 3 Interventional

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

NCT00747318
View directory record Official record
Conditions
Asthma
Interventions
SKP FlutiForm HFA pMDI
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Scottsdale, Arizona • Orange County, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

NCT01387230
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Sunset, Louisiana • Easley, South Carolina • Spartanburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

NCT03905330
View directory record Official record
Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions
Maralixibat, Placebo
Drug · Other
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

NCT00424528
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions
Arformoterol Tartrate Inhalation Solution, Tiotropium, Arformoterol and Tiotropium, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
45 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Jasper, Alabama • Tucson, Arizona • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fentanyl Patch Pharmacokinetics in Healthy Adults

NCT02531971
View directory record Official record
Conditions
Peer Review, Research
Interventions
Intravenous fentanyl citrate, Duragesic®, Mylan generic fentanyl
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

NCT04176133
View directory record Official record
Conditions
Healthy
Interventions
Entolimod, Placebo, Influenza vaccine
Drug
Lead sponsor
Robert J. Pignolo
Other
Eligibility
65 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

NCT01686828
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Interventions
Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects

NCT00529399
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

NCT00919763
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

NCT01686633
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate/ Vilanterol 200/25 mcg, Fluticasone Furoate/ Vilanterol 100/25 mcg, Fluticasone Furoate 100 mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
37
States / cities
Little Rock, Arkansas • Huntington Beach, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 25, 2026, 11:25 AM EDT
Terminated Phase 3 Interventional

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

NCT00295165
View directory record Official record
Conditions
Crohn Disease
Interventions
Sargramostim (Leukine), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
47
States / cities
Huntsville, Alabama • Orange, California • San Francisco, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 3 Interventional

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

NCT00020787
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
G17DT Immunogen, cisplatin, fluorouracil
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Developing Oral LT3 Therapy for Heart Failure - HFrEF

NCT04112316
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome
Interventions
Liothyronine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 25, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitric Oxide and the Autonomic Nervous System

NCT00178919
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure
Interventions
L-NMMA, Trimethaphan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 25, 2026, 11:25 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Non-surgical Alternatives to Treatment of Failed Medical Abortion

NCT02704481
View directory record Official record
Conditions
Abortion Failure
Interventions
Mifepristone, Misoprostol, Placebo mifepristone, Placebo misoprostol
Drug
Lead sponsor
Gynuity Health Projects
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
14
States / cities
Concord, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Oct 25, 2026, 11:25 AM EDT